Status:
COMPLETED
Fimasartan Blood Pressure Lowering After Acute Stroke
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Conditions:
Hypertension
Ischemic Stroke
Eligibility:
All Genders
19+ years
Brief Summary
This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients. All participants will ...
Eligibility Criteria
Inclusion
- Ischemic stroke or transient ischemic attack occurs after 7 days to 3 months.
- Mean blood pressure measured 3 times at the first visit (Visit 1) should be over 140 mmHg for systolic blood pressure or 90 mmHg for diastolic blood pressure
- Suitable for administration of fimasartan
- The life expectancy should be over 6 months.
Exclusion
- Patients already treated with antihypertensive medications
- Hemorrhagic stroke patients
Key Trial Info
Start Date :
July 28 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 5 2019
Estimated Enrollment :
1035 Patients enrolled
Trial Details
Trial ID
NCT03231293
Start Date
July 28 2016
End Date
April 5 2019
Last Update
November 4 2019
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Ansan Hospital
Ansan, South Korea
2
Hallym University Medical Center
Anyang, South Korea
3
Dong-A University Hospital
Busan, South Korea
4
Inje University Busan Paik Hospital
Busan, South Korea